Compare PIII & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PIII | MRKR |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 14.5M |
| IPO Year | 2021 | 2010 |
| Metric | PIII | MRKR |
|---|---|---|
| Price | $1.63 | $1.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $7.75 | ★ $7.87 |
| AVG Volume (30 Days) | 32.6K | ★ 1.7M |
| Earning Date | 11-09-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.61 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,459,080,000.00 | N/A |
| Revenue This Year | $7.84 | $15.22 |
| Revenue Next Year | $7.13 | $438.82 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.52 | $0.81 |
| 52 Week High | $16.89 | $2.46 |
| Indicator | PIII | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 21.10 | 54.73 |
| Support Level | N/A | $0.88 |
| Resistance Level | $3.07 | $1.32 |
| Average True Range (ATR) | 0.39 | 0.15 |
| MACD | -0.08 | 0.03 |
| Stochastic Oscillator | 1.41 | 33.33 |
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all. It includes utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of its providers, processing and payment of claims, and the establishment of a provider network for certain health plans.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).